Fluorinated cycloalkyl building blocks for drug discovery
OO Grygorenko, KP Melnykov, S Holovach… - …, 2022 - Wiley Online Library
The review covers various aspects of fluorinated cycloalkyl (C3− C7) building blocks for drug
discovery, including their synthesis, key physicochemical properties, and biological and …
discovery, including their synthesis, key physicochemical properties, and biological and …
Movement disorders research in 2021: cracking the paradigm
AJ Espay - The Lancet Neurology, 2022 - thelancet.com
The approval in 2021 of a disease-modifying treatment for Alzheimer's disease should have
been hailed as the most important advance in neurology of the century, validating the wider …
been hailed as the most important advance in neurology of the century, validating the wider …
The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson's disease
SS Karuppagounder, H Wang, T Kelly… - Science translational …, 2023 - science.org
Parkinson's disease (PD) is the second most prevalent neurodegenerative disease of the
central nervous system, with an estimated 5,000,000 cases worldwide. PD pathology is …
central nervous system, with an estimated 5,000,000 cases worldwide. PD pathology is …
Development of 18F-Labeled PET Tracer Candidates for Imaging of the Abelson Non-receptor Tyrosine Kinase in Parkinson's Disease
EJL Stéen, AY Park, W Beaino, CG Gadhe… - Journal of medicinal …, 2023 - ACS Publications
Activated Abelson non-receptor tyrosine kinase (c-Abl) plays a harmful role in
neurodegenerative conditions such as Parkinson's disease (PD). Inhibition of c-Abl is …
neurodegenerative conditions such as Parkinson's disease (PD). Inhibition of c-Abl is …
Discovery of novel tacrine derivatives as potent antiproliferative agents with CDKs inhibitory property
W Liu, L Wu, D Li, Y Huang, M Liu, W Liu, C Tian… - Bioorganic …, 2022 - Elsevier
Tacrine was the first approved drug by the FDA for the treatment of Alzheimer's disease (AD)
but was withdrawn from the market due to its dose-dependent hepatotoxicity. Herein, we …
but was withdrawn from the market due to its dose-dependent hepatotoxicity. Herein, we …
[HTML][HTML] The c-Abl/p73 pathway induces neurodegeneration in a Parkinson's disease model
T Marín, C Valls, C Jerez, T Huerta, D Elgueta… - IBRO Neuroscience …, 2022 - Elsevier
Parkinson's disease is the second most common neurodegenerative disorder. Although it is
clear that dopaminergic neurons degenerate, the underlying molecular mechanisms are still …
clear that dopaminergic neurons degenerate, the underlying molecular mechanisms are still …
Emerging targets signaling for inflammation in Parkinson's disease drug discovery
RC Khairnar, N Parihar, KS Prabhavalkar… - Metabolic Brain …, 2022 - Springer
Parkinson's disease (PD) patients not only show motor features such as bradykinesia,
tremor, and rigidity but also non-motor features such as anxiety, depression, psychosis …
tremor, and rigidity but also non-motor features such as anxiety, depression, psychosis …
c-Abl phosphorylation primes PARIS for neurodegeneration
F Giesert - Brain, 2021 - academic.oup.com
c-Abl phosphorylation primes PARIS for neurodegeneration | Brain | Oxford Academic Skip to
Main Content Advertisement Oxford Academic Journals Books Search Menu Information …
Main Content Advertisement Oxford Academic Journals Books Search Menu Information …
[PDF][PDF] Characterization of the phosphomimetic mutant Y39E of α-Synuclein
NM Böffinger - 2024 - rephip.unr.edu.ar
Characterization of the phosphomimetic mutant Y39E of α-Synuclein Page 1 Characterization
of the phosphomimetic mutant Y39E of α-Synuclein Dissertation for the award of the degree …
of the phosphomimetic mutant Y39E of α-Synuclein Dissertation for the award of the degree …
[HTML][HTML] Discount Codes
N Natalie - peptidesciences.com
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR
INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this …
INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this …